Skip to content

The effect of Helico bacter pylori treatment on decrease the insulin resistance and dose of insulin in diabetic person in kerman

The effect of Helico bacter pylori treatment on decrease the insulin resistance and dose of insulin in diabetic person in kerman

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230624058567N1
Enrollment
146
Registered
2023-06-26
Start date
2023-07-15
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection, diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention group: Patients whose diabetes has already been confirmed and the presence of Helicobacter infection in them has been confirmed by fecal antigen tests are first treated with standard trea

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age over 18 years and under 60 years Definite diagnosis of diabetes based on reliable sources

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study Hemoglobinopathy

Design outcomes

Primary

MeasureTime frame
Reducing insulin resistance and drug dosage. Timepoint: Three months after proving the eradication of the infection and without changing the drug regimen controlling diabetes and changing the lifestyle, the patient was tested by fasting plasma sugar and hemoglobin A1C in the same primary laboratory before treatment and tests related to the development of metabolic syndrome, including blood pressure and The patient's weight is assessed. Then, the effectiveness of infection treatment is evaluated on these parameters and compared with the level of these parameters before the eradication of this infection. Method of measurement: Three months after proving the eradication of the infection and without changing the drug regimen controlling diabetes and changing the lifestyle, the patient was tested by fasting plasma sugar and hemoglobin A1C in the same primary laboratory before treatment and tests related to the development of metabolic syndrome, including blood pressure and The patient's weight is assessed. Then, the effectiveness of infection treatment is evaluated on these parameters and compared with the level of these parameters before the eradication of this infection.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hossein Delkash

Kerman University of Medical Sciences

amirdelkash1990@gmail.com+98 34 3132 8000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026